Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine.

Murphy MB, Moncivais K, Caplan AI. · 2013

Read Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. by Murphy MB, Moncivais K, Caplan AI. (2013) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3849579.txt.

Introduction

Matthew B. Murphy, Kathryn Moncivais, and Arnold I. Caplan review mesenchymal stem cells in Experimental & Molecular Medicine in 2013. These adult stem cells can form bone, cartilage, and fat in a dish. Their larger promise, the authors argue, lies in the signals they send out once placed in the body.

Unlike a drug with one set dose, the cells read local cues and adjust what they release. Their calming effect on the immune system may matter most for healing. Cells from other donors have drawn wide interest, but a patient's own cells dodge many safety and rule hurdles. Fresh studies show own-cell therapy can work even in sick people. The review maps how these living drugstores sense and respond.

Catalog record

CREATORMurphy MB, Moncivais K, Caplan AI.
YEAR2013
COLLECTIONPAPERS
FORMATTXT
FILE SIZE96 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC3849579

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine By Matthew B Murphy, Kathryn Moncivais, Arnold I Caplan Published in: Experimental & Molecular Medicine DOI: 10.1038/emm.2013.94 ABSTRACT Mesenchymal stem cells (MSCs) are partially defined by their ability to differentiate into tissues including bone, cartilage and adipose in vitro, but it is their trophic, paracrine and immunomodulatory functions that may have the greatest therapeutic impact in vivo. Unlike pharmaceutical treatments that deliver a single agent at a specific dose, MSCs are site regulated and secrete bioactive factors and signals at variable concentrations in response to local microenvironmental cues. Significant progress has been made in understanding the biochemical and metabolic mechanisms and feedback associated with MSC response. The anti-inflammatory and immunomodulatory capacity of MSC may be paramount in the restoration of localized or systemic conditions for normal healing and tissue regeneration. Allogeneic MSC treatments, categorized as a drug by regulatory agencies, have been widely pursued, but new studies demonstrate the efficacy of autologous MSC therapies, even for individuals affected by a disease state. Safety and regulatory concerns surrounding allogeneic cell preparations make autologous and minimally manipulated cell therapies an attractive option for many regenerative, anti-inflammatory and autoimmune applications. INTRODUCTION Mesenchymal stem cells (MSCs) have been suggested to be patient-specific drugstores for injured tissue, and with good reason.1 What was originally believed to be a simple differentiation or lineage cascade of mesenchymal tissue cells has proven itself to be a much more elegant and complex entity. MSCs are now known to originate as pericytes, which function as surveyors of their kingdoms, capable of responding to local environmental stimuli with a myriad of beneficial interventions.2 The availability and versatility of these remarkable cells make them an excellent treatment option for a wide variety of clinical pathologies, and it falls to the scientific community to establish clear guidelines for the optimal administration of MSC-based therapies. In the following review, we survey a brief history of MSCs, their anti-inflammatory, immunomodulatory and paracrine effects, and the current status of MSC-based therapies for a multitude of clinical applications. IDENTIFICATION AND BIOLOGY OF MSCS Origin and early research The presence of regenerative cells was first hypothesized in the late nineteenth century by Cohnheim,3 who believed bone marrow (BM)-derived fibroblasts were involved in wound healing throughout the body. After the turn of the century, others described a fundamental relationship between developing mesoderm tissue and blood during embryogenesis.4 In the 1960s and 1970s, Friedenstein et al.5, 6, 7 described the isolation of stromal cells from BM by plastic adherence, a clonal or colony-forming capacity (that is, CFU-F), and the ability to regenerate or support ectopic bone, stroma and hematopoietic tissues. In the late 1980s and early 1990s, the heterogeneous population of MSC from BM was explored and found to be linked to the development of various mesenchymal tissues, as well as identifying the first surface antigens expressed by MSC (cluster of differentiation (CD)73 and CD105).8, 9, 10, 11, 12, 13, 14 Because of their linkage with the formation of mesenchymal tissues during embryonic development, these cells were termed ‘MSCs.'15 Tissue sources of MSC After their initial discovery in BM, MSCs have been isolated and characterized from several adult and fetal tissues, including adipose (fat), dermis (skin), synovial fluid, periosteum, umbilical cord blood, placenta and amniotic fluid. The reported MSC frequency (as measured by CFU-F) and native concentration from several adult human tissues are reported in Table 1. The relative abundance of MSCs throughout the body is understandable in light of recent findings that most, if not all, MSCs are of perivascular origin.16, 17, 18, 19, 20 Furthermore, there is a direct correlation between MSC frequency and blood vessel density in stromal vascularized tissue.21 MSCs and pericytes share the phenotypic surface markers melanoma cell adhesion molecule (CD146) and platelet-derived growth factor receptor.16, 22 It is hypothesized that pericytes are the in vivo source of MSCs, with cellular components protruding into the endothelial lumen of blood vessels to monitor and react to systemic signals.23, 24, 25, 26 The widespread distribution of perivascular precursors for MSCs would account for their ability to respond to injury by sensing and secreting chemokines locally in response to injury, infection or disease in all vascularized tissues of the body.1, 27, 28, 29 Capacity of MSC Trophic properties of MSC The primary trophic property of MSCs is the secretion of growth factors and other chemokines to induce cell proliferation and angiogenesis. MSCs express mitogenic proteins such as transforming growth factor-alpha (TGF-α), TGF-β, hepatocyte growth factor (HGF), epithelial growth factor (EGF), basic fibroblast growth factor (FGF-2) and insulin-like growth factor-1 (IGF-1) to increase fibroblast, epithelial and endothelial cell division.30, 31, 32, 33 Vascular endothelial growth factor (VEGF), IGF-1, EGF and angiopoietin-1 are released to recruit endothelial lineage cells and initiate vascularization.34 It has been hypothesized that an individual's genotype has a role in the expression of and reaction to these cytokines, providing credence to the philosophy of personalized medicine utilizing responsive agents (that is, MSCs) rather than a dose of recombinant proteins or autologous growth factors (for example, platelet-rich plasma).35 The trophic effects extend beyond cell proliferation to the reduction of scar tissue formation presumable by local cells secreting paracrine factors keratinocyte growth factor, stromal cell-derived factor-1 (SDF-1) and macrophage inflammatory protein-1 alpha and beta. Anti-inflammatory and immunomodulatory properties of MSC In many types of musculoskeletal trauma, inflammatory conditions at the site of injury impede the natural repair processes by local progenitor and mature cells. MSCs assist via paracrine mechanisms and modulate the regenerative environment via anti-inflammatory and immunomodulatory mechanisms. In response to inflammatory molecules such as interleukin-1 (IL-1), IL-2, IL-12, tumor necrosis factor-α (TNF-α) and interferon-gamma (INF-γ), MSCs secrete an array of growth factors and anti-inflammatory proteins with complex feedback mechanisms among the many types of immune cells (Table 2).36, 37, 38, 39, 40, 41 The key immunomodulatory cytokines include prostaglandin 2, TGF-β1, HGF, SDF-1, nitrous oxide, indoleamine 2,3-dioxygenase, IL-4, IL-6, IL-10, IL-1 receptor antagonist and soluble tumor necrosis factor-α receptor. MSCs prevent proliferation and function of many inflammatory immune cells, including T cells, natural killer cells, B cells, monocytes, macrophages and dendritic cells.37, 42, 43 Although MSCs across species are able to regulate T-cell activity, the mechanisms are not identical across mammalian species.44, 45 A characteristic of chronically inflamed environments is a persistent imbalance in the types of helper T cells and macrophages.46, 47, 48 MSCs indirectly promote the transition of TH1 to TH2 cells by reducing INF-γ and increasing IL-4 and IL-10.36, 49 The restored TH1/TH2 balance has been shown to improve tissue regeneration in cartilage, muscle and other soft tissue injuries, alleviate symptoms of autoimmune diseases and have an anti-diabetic effect.50, 51, 52, 53, 54 Similarly, reduction in INF-γ and secretion of IL-4 promotes a shift in macrophages from M1 (pro-inflammatory, anti-angiogenic and tissue growth inhibition) to M2 (anti-inflammatory, pro-remodeling and tissue healing) type, an effect required for skeletal, muscular and neural healing and regeneration.46, 52, 55, 56, 57, 58 Undifferentiated MSCs express low to medium levels of human leukocyte antigen (HLA) Class I and low levels of HLA Class II to avoid recognition by the immune system.59, 60 This property gives donor MSCs a so-called ‘stealth' ability to go undetected by a host immune system

Read the complete text